Trial · NCT01301027
Effect of Adipokines in Hemodialysis Patients
NCT01301027, Not applicable, Completed, University of Utah; results first posted 2016-10-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Adipokines in Hemodialysis Patients. Trials, record NCT01301027. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01301027
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Adipokines in Hemodialysis Patients
- NCT number
- NCT01301027
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 95 participants, actual
- Lead sponsor
- University of Utah
- Conditions
- End Stage Renal Disease
- Interventions
- Pioglitazone, Placebo
- First posted
- 2011-02-23
- Last updated
- 2016-10-03
- Results first posted
- 2016-10-03
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in High Molecular Weight Adiponectin (HMW-A) Concentration in Plasma From Baseline to 6 Months | Baseline and 6 months | The percent difference in HMW-A concentration geometric mean values from baseline to 6 months was calculated for each arm |
| Primary | Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 6 Months | Baseline and 6 months | The percent difference in hsCRP concentration geometric mean values from baseline to 6 months was calculated for each arm |
| Secondary | Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 6 Months | Baseline and 6 months | The percent difference in TNF-α concentration geometric mean values from baseline to 6 months was calculated for each arm |
| Secondary | Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 6 Months | Baseline and 6 months | The percent difference in IL-6 concentration geometric mean values from baseline to 6 months was calculated for each arm |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in High Molecular Weight Adiponectin (HMW-A) Concentration in Plasma From Baseline to 6 Months | Baseline and 6 months | 1 participant in the Pioglitazone group and 2 participants in the Placebo group had blood samples collected after the 10 week visit prior to their withdrawal. They did not complete the study, but their results were included in the 6-month analysis. | percent difference in geometric mean | GEOMETRIC_MEAN |
| PRIMARY | Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 6 Months | Baseline and 6 months | 1 participant in the Pioglitazone group and 2 participants in the Placebo group had blood samples collected after the 10 week visit and prior to their withdrawal. They did not complete the study, but their results were included in the 6-month analysis. | percent difference in geometric mean | GEOMETRIC_MEAN |
| SECONDARY | Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 6 Months | Baseline and 6 months | 1 participant in the Pioglitazone group and 2 participants in the Placebo group had blood samples collected after the 10 week visit and prior to their withdrawal. They did not complete the study, but their results were included in the 6-month analysis. | percent difference in geometric mean | GEOMETRIC_MEAN |
| SECONDARY | Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 6 Months | Baseline and 6 months | 1 participant in the Pioglitazone group and 2 participants in the Placebo group had blood samples collected after the 10 week visit and prior to their withdrawal. They did not complete the study, but their results were included in the 6-month analysis. | percent difference in geometric mean | GEOMETRIC_MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in High Molecular Weight Adiponectin (HMW-A) Concentration in Plasma From Baseline to 6 Months | Pioglitazone | 38.3 | 95% Confidence Interval 4.9 to 82.2 | percent difference in geometric mean | |
| Change in High Molecular Weight Adiponectin (HMW-A) Concentration in Plasma From Baseline to 6 Months | Placebo | -3.4 | 95% Confidence Interval -27.0 to 27.8 | percent difference in geometric mean | |
| Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 6 Months | Pioglitazone | -29.0 | 95% Confidence Interval -44.7 to -8.8 | percent difference in geometric mean | |
| Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 6 Months | Placebo | -1.8 | 95% Confidence Interval -23.8 to 26.5 | percent difference in geometric mean | |
| Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 6 Months | Pioglitazone | 44.9 | 95% Confidence Interval 32.9 to 58.1 | percent difference in geometric mean | |
| Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 6 Months | Placebo | 39.1 | 95% Confidence Interval 27.3 to 51.9 | percent difference in geometric mean | |
| Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 6 Months | Pioglitazone | -12.3 | 95% Confidence Interval -29.7 to 9.6 | percent difference in geometric mean | |
| Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 6 Months | Placebo | -12.5 | 95% Confidence Interval -30.1 to 9.5 | percent difference in geometric mean |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pioglitazone | 48 | |
| Overall Study | STARTED | Placebo | 47 | |
| Overall Study | COMPLETED | Pioglitazone | 40 | |
| Overall Study | COMPLETED | Placebo | 37 | |
| Overall Study | NOT COMPLETED | Pioglitazone | 8 | |
| Overall Study | NOT COMPLETED | Placebo | 10 |
Source ClinicalTrials.gov
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cardiac General - Volume Overload | Cardiac disorders | Pioglitazone | 4 | 48 | 4 |
| other | Cardiac General - Volume Overload | Cardiac disorders | Placebo | 3 | 47 | 3 |
| other | Diarrhea | Gastrointestinal disorders | Pioglitazone | 4 | 48 | 5 |
| other | Diarrhea | Gastrointestinal disorders | Placebo | 1 | 47 | 1 |
| other | Dizziness | Nervous system disorders | Pioglitazone | 3 | 48 | 5 |
| other | Dizziness | Nervous system disorders | Placebo | 2 | 47 | 2 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Pioglitazone | 3 | 48 | 3 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Placebo | 2 | 47 | 2 |
| other | Hyperkalemia | Metabolism and nutrition disorders | Pioglitazone | 3 | 48 | 3 |
| other | Hyperkalemia | Metabolism and nutrition disorders | Placebo | 0 | 47 | 0 |
1 to 10 of 54Source ClinicalTrials.gov
See all 54 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pioglitazone | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Pioglitazone | 16 | 48 |
| Total, other adverse events | Placebo | 6 | 47 |
| Total, serious adverse events | Pioglitazone | 11 | 48 |
| Total, serious adverse events | Placebo | 10 | 47 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK078112 | Adipokines in Hemodialysis Patients | BEDDHU, SRINIVASAN | UNIVERSITY OF UTAH | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2008 to 2011 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Pioglitazone vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01301027
GET https://conductscience.org/api/trials/v1/NCT01301027/events?page=2